18F-FET-PET-Based Dose Painting by Numbers with Protons

Rickhey, Mark; Morávek, Zdenek; Eilles, Christoph; Koelbl, Oliver; Bogner, Ludwig

doi:10.1007/s00066-010-2014-8

Cited by 19 publications

(7 citation statements)

References 36 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a previous study, Grosu et al [8] observed a significant survival benefit in re- current high-grade gliomas that were reirradiated on the basis of combined MRI and amino acid PET/SPECT compared to MRI-based treatment alone. The feasibility of a FET-based dose painting could be demonstrated in our own planning study [17] and as well a study by Rickhey et al [20,21].…”

Section: Discussionmentioning

confidence: 79%

Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 79%

Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Dose reduction may be important for toxicity reduction in particle therapy as it is in brachytherapy, and a prospective randomized trial of lower-dose (50 Gy) versus standard dose (70 Gy) proton radiation for small-to-moderate sized uveal melanoma showed no differences in a 5-year local or systemic recurrence or visual acuity loss, suggesting lower dose may be acceptable moving forward (44). In the past decade or two, linear accelerator (LINAC) stereotactic RT (SRT), or SRS with either LINAC or gamma knife has been investigated for its potential as an alternative option to proton beam (46)(47)(48)(49)(50)(51)(52)(53). The initial experiences showed that SRT and SRS offer a noninvasive alternative to enucleation and brachytherapy in the management of uveal melanoma, with similar outcome to proton beam therapy (46)(47)(48)(49)(50)(51)(52)(53).…”

Section: Definitive Rt For Ocular Melanomasmentioning

confidence: 99%

Radiation Therapy for Melanoma

Shi

2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Although melanoma is a relative radioresistant tumor, radiation therapy (RT) remains a valid and effective treatment option for the management of melanoma. RT as a primary treatment is often offered in well-defined situations, such as medical inoperability, lentiginous melanoma, mucosal melanoma, and ocular melanoma. Adjuvant RT following lymphadenectomy in node-positive melanoma patients prevents local and regional recurrence; however, the role of adjuvant RT remains controversial and underutilized due to lack of overall survival benefit. On the other hand, RT is highly effective in providing symptom palliation for metastatic melanoma and is widely used. Advanced RT technologies such as stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) can achieve excellent local control with minimum toxicities. They are commonly used in the management of brain, lung, spine, and liver metastases. Most recently, it is under active investigation on combining RT with new systemic options, such as targeted therapy, or immunotherapy. The advancements in the treatment of patients with melanoma highlight the importance of multidisciplinary management in this disease. Radiation therapy will continue to be one of the key therapeutic options.

show abstract

“…Der Tracer [18 F] -3,4-dihydroxyphenylalanin (F-DOPA) stellt eine nicht-proteinogene α-Aminosäure dar und kann ebenfalls in der neuroonkologischen Diagnostik eingesetzt werden [27]. Die AS-PET unterscheidet zuverlässig zwischen therapiebedingten Gewebeveränderungen und einem Gliomrezidiv [3,22,40,43], liefert entscheidende Informationen zur Planung von stereotaktischen Biopsien oder navigierten Resektionen [23,35,41] und eignet sich zur Präzisierung des Zielvolumens bei der Strahlentherapieplanung [14,32,36,44,45]. Ferner kann die FET-PET zur Beurteilung des Ansprechens eines Hirntumors auf die Therapie eingesetzt werden [36,38,39,46,48].…”

Section: Rolle Der Pet In Der Diagnostik Von Hirntumoren Im Kindes-ununclassified

Rolle der PET in der Diagnostik von Hirntumoren im Kindes- und Jugendalter

et al. 2014

View full text Add to dashboard Cite

Zusammenfassung ▼Der Stellenwert der PET mit radioaktiv markierten Aminosäuren in der neuroonkologischen Diagnostik ist in vielen Studien validiert. Die Methode kann auch bei pädiatrischen Patienten zur Früherkennung von Rezidiv-/Resttumoren und vor allem zur Differenzierung eines vitalen Tumors von therapiebedingten Veränderungen eingesetzt werden. lm Rahmen einer prospektiven, multizentrischen Studie (FET PET 2010) soll die Genauigkeit der FET-PET in der Nachsorge von kindlichen Hirntumoren im Vergleich zum gegenwärtigen diagnostischen "Goldstandard" MRT vergleichen werden. Abstract ▼The value of amino acid PET in neurooncology was validated by numerous studies. This method might be useful in paediatric patients for early diagnosis of residual/recurrent tumours and especially for differentiation of the viable tumour from therapy-induced tissue changes. The aim of a multicentre prospective study (FET PET 2010) is to estimate the accuracy of FET-PET in the follow-up of paediatric brain tumours in comparison to the current diagnostic "gold standard" MRI.Heruntergeladen von: University of Florida. Urheberrechtlich geschützt. Pädiatrische Nuklearmedizin 255Plotkin M et al. Rolle der PET in … Der Nuklearmediziner 2014; 37: 254-257

show abstract

18F-FET-PET-Based Dose Painting by Numbers with Protons

Abstract: The presented investigation fortifies the feasibility of (18)F-FET-PET-based dose painting with protons.

Cited by 19 publications

References 36 publications

Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas

Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas

Radiation Therapy for Melanoma

Rolle der PET in der Diagnostik von Hirntumoren im Kindes- und Jugendalter

Contact Info

Product

Resources

About